Exhibit 99.1 Cipher Mining Provides Second Quarter 2025 Business Update Second Quarter 2025 Revenue of $44m and Non-GAAP Adjusted Earnings of $30m Black Pearl Phase I exceeds growth targets, bringing Cipher's total self-mining capacity to ~16.8 EH/s and on track to deliver ~23.5 EH/s by the end of the third quarter 2025 NEW YORK— August 7, 2025 —Cipher Mining Inc. (NASDAQ: CIFR) ("Cipher" or the "Company") today announced its second quarter 2025 financial results, as well as an update on its operations and ...

[Part I — Financial Information](index=5&type=section&id=Part%20I%20%E2%80%94%20Financial%20Information) [Item 1. Consolidated Financial Statements](index=5&type=section&id=Item%201.%20Consolidated%20Financial%20Statements) The report presents unaudited consolidated financial statements for Simon and its Operating Partnership [Consolidated Financial Statements of Simon Property Group, Inc.](index=6&type=section&id=Consolidated%20Financial%20Statements%20of%20Simon%20Property%20Group%2C%20Inc.) Simon Property Group, Inc. reported lower net income and EPS for H1 2025 despite an increase in total assets Simon Property Group, Inc. - Key Financials (Six Months Ended June 30, in millions) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | **Total Revenue** | $2,971.5 | $2,900.9 | | **Consolidated Net Income** | $1,121.5 | $1,410.6 | | **Net Income Attributable to Common Stockholders** | $969.8 | $1,225.2 | | **Diluted EPS** | $2.97 | $3.76 | Simon Property Group, Inc. - Balance Sheet Summary (in millions) | Metric | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **Total Assets** | $33,295.6 | $32,405.7 | | **Total Liabilities** | $30,204.5 | $28,806.2 | | **Total Stockholders' Equity** | $2,451.5 | $2,941.9 | Simon Property Group, Inc. - Cash Flow Summary (Six Months Ended June 30, in millions) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | **Net Cash from Operating Activities** | $2,042.6 | $1,836.3 | | **Net Cash (Used in) Provided by Investing Activities** | $(1,088.4) | $588.2 | | **Net Cash Used in Financing Activities** | $(1,123.0) | $(2,359.0) | | **(Decrease) Increase in Cash** | $(168.9) | $65.4 | [Consolidated Financial Statements of Simon Property Group, L.P.](index=11&type=section&id=Consolidated%20Financial%20Statements%20of%20Simon%20Property%20Group%2C%20L.P.) The Operating Partnership's financials mirror Simon's, with key differences in the equity section Simon Property Group, L.P. - Key Financials (Six Months Ended June 30, in millions) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | **Total Revenue** | $2,971.5 | $2,900.9 | | **Consolidated Net Income** | $1,121.5 | $1,410.6 | | **Net Income Attributable to Unitholders** | $1,120.6 | $1,408.7 | | **Diluted EPU** | $2.97 | $3.76 | - The assets and liabilities of the Operating Partnership are the same as Simon Property Group, Inc, with the main balance sheet difference being the presentation of **Partners' Equity** instead of Stockholders' Equity[11](index=11&type=chunk)[14](index=14&type=chunk)[38](index=38&type=chunk) [Condensed Notes to Consolidated Financial Statements](index=16&type=section&id=Condensed%20Notes%20to%20Consolidated%20Financial%20Statements) Notes detail acquisitions, investments, debt structure, and reconciliations of key financial metrics - As of June 30, 2025, the company owned or had an interest in **194 U.S. properties** and **38 international properties**, along with an **88% interest in TRG** and a **22.4% equity stake in Klépierre**[51](index=51&type=chunk) - In 2025, the company acquired the remaining interests in Brickell City Centre's retail component for **$497.7 million**, Briarwood Mall, and two luxury outlets in Italy for **$392.4 million**[98](index=98&type=chunk)[99](index=99&type=chunk)[100](index=100&type=chunk) - In Q1 2024, the company sold its remaining interest in Authentic Brands Group (ABG) for **$1.2 billion**, resulting in a pre-tax gain of **$414.8 million**[116](index=116&type=chunk) Consolidated Debt Summary (June 30, 2025) | Debt Type | Amount | | :--- | :--- | | Mortgages and unsecured indebtedness | $25,401.3M | | - Senior Unsecured Notes | $18.8B | | - Unsecured Term Loan | €350.0M | | - Credit Facility Outstanding | $460.0M | | - Supplemental Facility Outstanding | €500.0M | | - Mortgage Debt | $5.3B | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=49&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes a decrease in EPS due to a prior-year gain, highlighting strong core operational growth Key Performance Indicators (U.S. Malls and Premium Outlets) | Metric | June 30, 2025 | June 30, 2024 | | :--- | :--- | :--- | | **Ending Occupancy** | 96.0% | 95.6% | | **Average Base Minimum Rent (psf)** | $58.70 | $57.94 | - The decrease in diluted EPS for H1 2025 was primarily driven by a **$414.8 million pre-tax gain** on the sale of the company's ABG interest in Q1 2024, which was not repeated in 2025[197](index=197&type=chunk) - Portfolio Net Operating Income (NOI) **increased by 4.2%** for the first six months of 2025 compared to the same period in 2024, indicating strong underlying operational performance[200](index=200&type=chunk) FFO Reconciliation Summary (Diluted Per Share) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | **Diluted Net Income per Share** | $2.97 | $3.76 | | **Diluted FFO per Share** | $5.82 | $6.46 | | **Real Estate FFO per Share** | $6.01 | $5.84 | [Item 3. Qualitative and Quantitative Disclosures About Market Risk](index=75&type=section&id=Item%203.%20Qualitative%20and%20Quantitative%20Disclosures%20About%20Market%20Risk) Market risk disclosures remain materially unchanged from the 2024 Annual Report on Form 10-K - There have been **no material changes** in market risk disclosures since the 2024 Annual Report on Form 10-K[279](index=279&type=chunk) [Item 4. Controls and Procedures](index=75&type=section&id=Item%204.%20Controls%20and%20Procedures) Management confirmed the effectiveness of disclosure controls with no material changes to internal controls - Management, including the CEO and CFO, concluded that disclosure controls and procedures for both Simon and the Operating Partnership were **effective** as of June 30, 2025[281](index=281&type=chunk)[284](index=284&type=chunk) - **No changes occurred** during the quarter that materially affected, or are reasonably likely to materially affect, internal control over financial reporting for either entity[282](index=282&type=chunk)[285](index=285&type=chunk) [Part II — Other Information](index=76&type=section&id=Part%20II%20%E2%80%94%20Other%20Information) [Item 1. Legal Proceedings](index=76&type=section&id=Item%201.%20Legal%20Proceedings) Ongoing legal proceedings are not expected to have a material adverse effect on the company - The company does not expect current legal proceedings to have a **material adverse effect** on its financial condition or operations[286](index=286&type=chunk) [Item 1A. Risk Factors](index=76&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported since the 2024 Annual Report on Form 10-K - **No material changes** to the company's risk factors were reported for the quarter[287](index=287&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=76&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered equity sales or share repurchases during the quarter - **No unregistered sales** of equity securities were made by either Simon or the Operating Partnership during Q2 2025[288](index=288&type=chunk)[290](index=290&type=chunk) - As of June 30, 2025, **no shares had been repurchased** under the $2.0 billion stock repurchase plan authorized in February 2024[289](index=289&type=chunk) - The Operating Partnership redeemed **300 limited partner units for $50,000** during the quarter[291](index=291&type=chunk) [Item 5. Other Information](index=76&type=section&id=Item%205.%20Other%20Information) The Audit Committee approved additional audit and non-audit services from its accounting firm - The Audit Committee approved additional audit and non-audit services from **Ernst & Young LLP** during the quarter[294](index=294&type=chunk) [Item 6. Exhibits](index=78&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the report, including required CEO/CFO certifications - The report includes standard exhibits such as organizational documents and **CEO/CFO certifications** under Sarbanes-Oxley Sections 302 and 906[296](index=296&type=chunk)

Exhibit 99.1 • RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025 • Phase 2 trial of RAP-219 in bipolar mania has been initiated and is enrolling patients; trial remains on track, with topline results anticipated in the first half of 2027 • Ended the quarter with $260.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2 ...

EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights ROCKVILLE, Md., August 7, 2025 (PR Newswire) -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2025. "Our REGENXBIO team is accelerating multiple first or best-in-class gene therapies designed to improve the lives of patients and families facing serious diseases like Duchenne, Hunter syndrome, and retinal diseases. We continued our s ...

Exhibit 99.1 LENSAR Reports Second Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla. (August 7, 2025) – LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company), a global medical technology company focused ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41199 Amylyx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ...

[The Dixie Group Q2 2025 Earnings Release](index=1&type=section&id=The%20Dixie%20Group%20Q2%202025%20Earnings%20Release) [Financial Highlights](index=1&type=section&id=Financial%20Highlights) The company reported slightly lower sales but significantly improved operating and net income for Q2 2025, driven by better margins and cost controls Q2 2025 vs Q2 2024 Performance | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Net Sales | $68,573,000 | $70,507,000 | -2.7% | | Operating Income | $3,189,000 | $2,295,000 | +38.9% | | Net Income (Continuing Ops) | $1,254,000 | $667,000 | +88.0% | | Diluted EPS (Continuing Ops) | $0.08 | $0.04 | +100.0% | First Half 2025 vs First Half 2024 Performance | Metric | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Net Sales | $131,563,000 | $135,761,000 | -3.1% | | Operating Income | $3,200,000 | $1,437,000 | +122.7% | | Net Loss (Continuing Ops) | ($328,000) | ($1,743,000) | +81.2% improvement | | Diluted EPS (Continuing Ops) | ($0.02) | ($0.12) | +83.3% improvement | [Management Commentary and Business Operations](index=1&type=section&id=Management%20Commentary%20and%20Business%20Operations) Management attributes strong Q2 profitability to cost reductions, with soft surface sales outperforming the market despite challenges in hard surfaces [Overall Performance and Cost Management](index=1&type=section&id=Overall%20Performance%20and%20Cost%20Management) The company achieved a **$1.2 million net income** in Q2, driven by improved margins and a **$12.6 million** annual cost reduction plan - Achieved a net income of **$1.2 million** in the second quarter, despite lower year-over-year sales volume[4](index=4&type=chunk) - Operating margins improved to **29.2% of net sales** compared to 28.1% in the same quarter of the prior year[4](index=4&type=chunk) - A cost reduction plan is currently estimated to produce **$12.6 million in reduced spending** year over year, contributing to favorable results[4](index=4&type=chunk) [Segment Performance and Product Launches](index=1&type=section&id=Segment%20Performance%20and%20Product%20Launches) Soft surface sales outperformed the declining market, while hard surface growth in wood was offset by challenges in the TRUCOR® segment - Soft surface sales were relatively flat year-over-year, outperforming the broader industry which is believed to have **declined by 7%**[5](index=5&type=chunk) - Key growth drivers in soft surfaces included the **DuraSilk™ SD collection** and the high-end decorative segment[5](index=5&type=chunk) - The hard surface segment experienced **over 10% year-over-year growth** in net sales of Fabrica wood products, but the TRUCOR® segment faced challenges due to low inventory and supply chain issues[8](index=8&type=chunk) - The company launched **five new soft surface introductions** and **five new hard surface collections** during the second quarter to stimulate sales[6](index=6&type=chunk)[9](index=9&type=chunk) [Marketing and Outlook](index=2&type=section&id=Marketing%20and%20Outlook) The company is leveraging digital marketing and cost controls to navigate market headwinds while preparing for future demand - Continued digital marketing partnerships with Roomvo and Broadlume are showing promising results in lead generation, online sample ordering, and room visualizations[10](index=10&type=chunk) - Management acknowledges that the industry continues to be negatively impacted by **inflationary pressures, high interest rates, and low consumer confidence**[11](index=11&type=chunk) - The company believes it has taken appropriate actions through cost reductions and operational improvements to manage the current slowdown and optimize returns when market conditions improve[11](index=11&type=chunk) [Detailed Financial Analysis](index=2&type=section&id=Detailed%20Financial%20Analysis) Improved operating margins and lower expenses boosted profitability, while the balance sheet reflects stable inventory and adequate liquidity [Profitability Analysis](index=2&type=section&id=Profitability%20Analysis) Q2 operating margin improved to **29.2%** due to efficiencies and cost reductions, with selling and administrative expenses also declining Operating Margin Comparison | Period | 2025 | 2024 | | :--- | :--- | :--- | | Q2 | 29.2% | 28.1% | | H1 | 28.1% | 26.2% | Selling & Administrative Expenses | Period | 2025 | 2024 | | :--- | :--- | :--- | | Q2 | $16.8 million | $17.4 million | | H1 | $33.7 million | $33.7 million | [Balance Sheet, Cash Flow, and Liquidity](index=2&type=section&id=Balance%20Sheet%2C%20Cash%20Flow%2C%20and%20Liquidity) The balance sheet shows stable inventory and a slight debt increase, with **$13.1 million** available under the senior credit facility - Receivables increased by **$5.6 million** and inventory was slightly higher at **$67.4 million** compared to fiscal year-end 2024[13](index=13&type=chunk) - Debt increased by **$1.1 million** in the first six months of 2025, with interest expense rising to **$1.9 million** in Q2 from $1.6 million in Q2 2024 due to higher interest rates[13](index=13&type=chunk) - Availability under the senior lending facility was **$13.1 million** at the end of Q2 2025, subject to a $6.0 million minimum excess availability requirement[13](index=13&type=chunk) [Consolidated Financial Statements](index=3&type=section&id=Consolidated%20Financial%20Statements) This section presents the unaudited consolidated statements of operations and balance sheets for Q2 and H1 2025 [Consolidated Condensed Statements of Operations](index=3&type=section&id=Consolidated%20Condensed%20Statements%20of%20Operations) The statement details revenues, costs, and profits for Q2 and H1 2025, showing lower sales but higher quarterly operating income Q2 Statement of Operations Highlights (in thousands) | Account | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | NET SALES | $68,573 | $70,507 | | GROSS PROFIT | $20,016 | $19,813 | | OPERATING INCOME | $3,189 | $2,295 | | INCOME FROM CONTINUING OPERATIONS | $1,254 | $667 | | NET INCOME | $1,160 | $603 | H1 Statement of Operations Highlights (in thousands) | Account | H1 2025 | H1 2024 | | :--- | :--- | :--- | | NET SALES | $131,563 | $135,761 | | GROSS PROFIT | $36,918 | $35,622 | | OPERATING INCOME | $3,200 | $1,437 | | LOSS FROM CONTINUING OPERATIONS | ($328) | ($1,743) | | NET LOSS | ($537) | ($1,891) | [Consolidated Condensed Balance Sheets](index=4&type=section&id=Consolidated%20Condensed%20Balance%20Sheets) The balance sheet presents the company's financial position as of June 28, 2025, showing an increase in total assets and liabilities Balance Sheet Highlights (in thousands) | Account | June 28, 2025 | Dec 28, 2024 | | :--- | :--- | :--- | | **ASSETS** | | | | Cash and cash equivalents | $4,386 | $19 | | Inventories, net | $67,381 | $66,852 | | TOTAL CURRENT ASSETS | $106,623 | $95,839 | | TOTAL ASSETS | $188,383 | $175,872 | | **LIABILITIES & EQUITY** | | | | Accounts payable | $26,319 | $14,884 | | Current portion of long-term debt | $57,311 | $53,818 | | TOTAL CURRENT LIABILITIES | $104,282 | $88,719 | | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $188,383 | $175,872 |

Exhibit 99.1 Appian Announces Second Quarter 2025 Financial Results Second quarter cloud subscriptions revenue increased 21% year-over-year to $106.9 million Second quarter total revenue increased 17% year-over-year to $170.6 million McLean, VA – August 7, 2025 – Appian (Nasdaq: APPN) today announced financial results for the second quarter ended June 30, 2025. "Appian AI drove strong financial results in the second quarter of 2025, with higher prices and a larger pipeline," said Matt Calkins, CEO & Founder ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Co ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance – LINZESS (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – – Plans to align with FDA on confirmatory Phase 3 trial design in Q4 2025 – – Progressing previously announced strategic alternatives review to maximize shareholder value – BOSTON, Mass., August 7, 2025 — Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotec ...